Outcomes of using flash glucose monitoring (FGM) have been reported in adults and in clinical trials, less information is available in children and adolescents during real-life settings. This study is evaluating the use and outcomes of FGM in children and teenagers with type 1 diabetes.
FGM had been initiated in children and adolescents (6 to 17 years) from April to June 2019 in real-life settings. Educational program included 2 visits in groups of 4-8 patients at the time of initiation and 1 individualised visit during of first month of sensor wearing.
A total of 31 children and teenagers (54.8% male; age 11.9±3.0 years, type 1 diabetes duration 4.7±3.1 years) had been included from April to June of 2019. Baseline HbA1c was 8.4±1.1. During the first 2 weeks of sensor wearing 75.5±27.9 % of data were collected. TIR was 38.8±15.7%, with 56.5±17.7% of time in hyperglycaemia (>180mg/dL) and 4.9±4.5% of time in hypoglycaemia (<70mg/dL). Patients performed 7.5±1.8 SMBG/day before FGM initiation and scanned 7.5±5.5 times/day during the first 2 weeks of sensor wearing. Diabetes related quality of life had been measured (PedsQL tests for patients and parents) baseline.
The same data will be collected at 6 months and compared with baseline. Moreover, % of therapy discontinuation, the reasons and technical incidences will be collected.
The evaluation of the effectiveness in terms of metabolic control and quality of life of FGM in real-life settings is important in order to corroborate the clinical trials data.